Chronic lymphocytic leukemia (CLL) is a B-cell lymphoid neoplasm with deregulated apoptosis and overexpression of several antiapoptotic BCL-2 proteins. GX15-070/Obatoclax is a small-molecule BH3 mimetic compound that has shown activity against several hematologic malignancies and solid tumors. In the present work, we report that GX15-070 led to the disruption of BCL-2/BIM and MCL-1/BAK complexes in CLL cells, followed by the activation of the mitochondrial apoptotic pathway. CLL cells showed lower sensitivity to GX15-070 than primary mantle cell lymphoma (MCL) ones, in correlation with higher levels of phosphorylated BCL-2 at serine 70 residue (pBCL-2(Ser70)) in CLL cells. Decrease in BCL-2 phosphorylation by extracellular signal-regulated kinase (ERK)1/2 inhibition increased CLL sensitivity to GX15-070, while blocking BCL-2 dephosphorylation using a PP2A antagonist reduced the activity of this BH3 mimetic. GX15-070 activity was increased by cotreatment with the proteasome inhibitor bortezomib. However, as proteasome inhibition led to the accumulation of phosphorylated BCL-2, the degree of interaction between GX15-070 and bortezomib was regulated by basal pBCL-2(Ser70) levels. These results support the role of BCL-2 phosphorylation as a mechanism of resistance to BH3 mimetic compounds, and demonstrate that combination approaches including ERK inhibitors could enhance BH3 mimetics activity both alone or in combination with proteasome inhibitors.
Introduction
Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries and is characterized by the accumulation of CD5-positive monoclonal B cells. 1 New prognostic markers have recently been identified, among them the mutational status of the immunoglobulin variable heavy chain genes, the expression of the z-chain-associated protein 70 kDa (ZAP-70) and the CD38 antigen as well as certain cytogenetic abnormalities. 1, 2 The clonal excess of B cells is caused by a concomitant defect in both cell death and proliferation. 3 A key factor that may explain this inappropriate cell survival of CLL is the imbalanced expression of BCL-2 family proteins. 4 High levels of antiapoptotic BCL-2 family proteins are associated with ex vivo resistance to apoptosis, poor response to chemotherapy and advanced stage CLL. 5 The BCL-2 family of proteins controls the commitment to apoptotic cell death in mammals. The pro-survival members (BCL-2, BCL-X L , MCL-1, BCL-W and A1) oppose two proapoptotic groups: the multidomain proteins (BAX, BAK and BOK) and the BH3-only proteins (BIM, PUMA, NOXA, BAD, BID, BMF, BIK and HRK). A balance between pro-survival and pro-death BCL-2 members dictates the outcome of many death-initiating signaling pathways. 6 Futhermore, BH3-only members become activated in response to a wide range of death and stress signals. Certain BH3-only proteins called 'activators', such as BIM and BID, induce the conformational changes of BAX and BAK. Others termed 'sensitizers' (such as NOXA, PUMA, BAD and so on), liberate BAK from MCL-1 and BCL-X L sequestration and cooperate in freeing the activator BH3-only type from the antiapoptotic members. 7, 8 BCL-2 proteins are tightly regulated both at transcriptional and post-translational levels and phosphorylation may play a determinant role in the regulation of their function. 9 It is well known that BCL-2 protein undergoes multisite phosphorylation localized at the loop region that includes Thr56, Thr69, Ser70, Thr74 and Ser87 in response to diverse type of stimuli. Depending on the stimulus, BCL-2 phosphorylation has been linked either to cell survival 10 or to cell death. 11 Interestingly, BCL-2 phosphorylation at Ser70 has been found necessary for full and potent antiapoptotic function; 10, 12, 13 it has also been associated with poor survival in acute myeloid leukemia (AML). 14 In addition, BCL-2 phosphorylation may also regulate its interaction with mutidomain (BAX) and BH3-only proapoptotic (BIM and BID) members 15 and protect BCL-2 from ubiquitin-dependent degradation by proteasome. 16, 17 On the basis of CLL biology, antiapoptotic BCL-2 proteins represent an attractive target for the treatment of this neoplasm, and several attempts have been made to shut off one or more of them, namely, the small-molecule compound HA14-1, the antisense Oblimersen and the BH3 mimetic ABT-737. [18] [19] [20] In this context GX15-070/Obatoclax is a small-molecule pan-BCL-2 inhibitor, which binds to BCL-2, BCL-W, BCL-X L and MCL-1. 21 This compound has been designed to mimic proapoptotic BH3-only proteins in its binding to the antiapoptotic BCL-2 family members, and appears to fall into the class of BH3 'sensitizers' category. In a recent paper, we described that GX15-070 induces apoptosis in mantle cell lymphoma (MCL) and synergizes with bortezomib by enhancing NOXA-mediated activation of BAK.
22 GX15-070 is in clinical trials for several cancer types employed both as a single agent and in combination therapy. In general, GX15-070 is well tolerated and results in clinical and biological activity. Namely, phase 1 trials in CLL are under evaluation, 23 and phase 1 and 2 trials are on going for GX15-070 in combination with bortezomib in relapsed MCL patients (http://clinicaltrials.gov, trial number NCT00407303).
The purpose of this work was to study the key factors that determine the sensitivity of CLL to GX15-070 and its interaction with bortezomib. These studies may contribute to the rational use of BH3 mimetic compounds, alone or in combination with proteasome inhibitor-based therapies, hopefully improving the outcome of CLL patients.
Patients, materials and methods

Patients
Cells from 20 patients diagnosed of CLL according to the World Health Organization classification who had not received treatment for the past 3 months were studied. Tumor cells were obtained from peripheral blood and the percentage of malignant cells (CD19 þ and CD5 þ ) was determined by flow cytometry. All samples included in the study had more than 95% of tumor cells. ZAP-70 expression levels were determined as previously described. CLL was considered ZAP-70 þ when more than 20% of CLL cells expressed ZAP-70 protein by flow cytometry analysis. 2 The clinical characteristics of these patients are listed in Table 1 . Clinical data of MCL patients included have been reported in a previous study. 22 In all cases, an informed consent was obtained in accordance with the guidelines and the approval of the Ethical Committee of the Hospital Clínic (Barcelona, Spain) and the Declaration of Helsinki.
Isolation and culture of primary cells
Mononuclear cells from peripheral blood samples were isolated by Ficoll/Hypaque sedimentation (Seromed, Berlin, Germany). Cells were either used directly or cryopreserved in liquid nitrogen in the presence of 10% dimethyl sulfoxide and 60% heat-inactivated fetal calf serum (FCS; Gibco, Paisley, Scotland, UK). Manipulation due to freezing/thawing did not influence cell response. Cells from CLL patients (2 Â 10 6 cells per ml) were cultured in RPMI 1640 culture medium (Gibco), supplemented with 10% FCS, 2 mM glutamine and 50 mg/ml penicillinstreptocycin, at 37 1C in a humidified atmosphere containing 5% carbon dioxide. Cells were incubated for 3-40 h with GX15-070 (kindly provided by GeminX Biotechnologies, Montreal, Quebec, Canada), either alone or in combination with the proteasome inhibitor bortezomib (kindly provided by Millenium Pharmaceuticals, Cambridge, MA, USA). When specified, cells were preincubated for 1 h with the MEK1/ERK (extracellular signal-regulated kinase) inhibitor PD98059 (Calbiochem, Darmstadt, Germany) or the PP2A/PP1 inhibitor okadaic acid (Sigma, St Louis, MO, USA) prior to adding GX15-070 or bortezomib. In all experiments, the viability of control cells exceeds 80%.
Cell lines
H1299 cells were maintained in minimum essential medium -a supplemented with 10% FBS and 100 U/ml streptomycin and penicillin. The phosphomutant S70E-BCL-2b5 plasmid was constructed by standard PCR-directed mutagenesis. The oligonucleotides used were: 5 0 -GCACCGGGCTTCTTCGAGTCCCAG CCCGG-3 0 and 5 0 -CCGGGCTGGGACTCGAAGAAGCCCGGT GC-3 0 . H1299 cell line expressing BCL-2b5 or S70E-BCL-2b5 were generated as described previously. 24 
Immunoblotting and immunoprecipitation
Cells were lysed in Triton buffer (1% Triton X-100, 50 mM Tris (tris-hydroxymethyl-aminomethane)-HCl, pH 7.6, 150 mM NaCl, 1 mM EDTA (ethylenediaminetetraacetic acid), 1 mg/ml leupeptin, 1 mg/ml aprotinin, 1 mM PMSF (phenylmethanesulfonyl fluoride), 1 mM sodium orthovanadate, 2 mM sodium pyrophosphate, 1 mM sodium fluoride and 2 mM sodium b-glycerophosphate). Solubilized proteins were analyzed in 12% polyacrylamide gels and western blot analysis was performed as previously described. 25 Equal protein loading was confirmed by analyzing a-tubulin expression. Chemiluminiscence was detected using LAS3000 Fujifilm device and relative protein quantification was done with Image Gauge Fujifilm software (Fuji, Tokyo, Japan). The following monoclonal and polyclonal antibodies were used: MCL-1 (S-19), BCL-X L/S (2H12), phospho-ERK1/2 and BCL-2 (100; Santa Cruz Biotechnology, Santa Cruz, CA, USA); MCL-1 (clone 22; BD-Pharmingen, San Diego, CA, USA); BCL-2 (Dako, Glostrup, Denmark); BIM (Calbiochem); BAK (NT) (Upstate, Lake Placid, NY, USA); phospho-BCL-2 (Ser70) (Cell Signalling Technologies, Beverly, MA, USA) and anti-a-tubulin (Sigma). MCL-1 immunoprecipitation was performed as previously described. 22 BCL-2 immunoprecipitation was performed similarly, except that 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS) buffer (1% CHAPS, w/v, 100 mM NaCl, 5 mM Na 3 PO 4 , 2.5 mM EDTA, 1 mg/ml leupeptin, 1 mg/ml aprotinin and 1 mM PMSF) and anti-BCL-2 (100) antibody (Santa Cruz Biotechnology) were used. Membranes were probed with polyclonal anti-BIM (Calbiochem) and anti-BCL-2 (Dako) antibodies.
Flow cytometry analysis of apoptosis
Phosphatidylserine (PS) exposure was quantified by surface Annexin V-APC staining (Bender Medsystems, Burlingame, CA, Genetic alterations assessed by FISH of del11q, del13q, del17p and trisomy 12.
pBCL-2(Ser70) modulates CLL sensitivity to GX150-70 P Pérez-Galán et al USA) as previously described. 22 A total of 10 000 cells per sample were acquired in a FACSCalibur flow cytometer using Cell Quest software (Becton Dickinson, San Jose, CA, USA). The lethal dose 50 (LD 50 ) was defined as the concentration of the drug required to reduce cell viability by 50%. Changes in mitochondrial transmembrane potential (DC m ) were evaluated by staining cells with 20 nM 3,3 0 -diexyloxacarbocyanine iodide (DiOC 6 [3] ; Molecular Probes, Eugene, OR, USA). BAX and BAK conformational changes proteins were also analyzed by flow cytometry as previously described. 22 Labeled cells were acquired in a FACScan flow cytometer. Analysis of the labeled populations was assessed using Paint-a-Gate software (Becton Dickinson).
Statistical analysis
Results are expressed as mean±standard deviation (s.d.) of three independent experiments. Levels of significance were evaluated by two-tailed t-test using GraphPad, Prism 4.0 software (GraphPad Software, Inc., La Jolla, CA, USA). P values in between 0.01oPo0.05 were considered significant (*), very significant (**) when 0.001oPo0.01 and extremely significant (***) when Po0.001. Synergism, additive effects and antagonism were assessed using Calcusyn software v2.0 (Biosoft, Ferguson, MO, USA). The interaction among drugs was found additive when the combination index (CI) equaled 1, and synergistic when CI values were less than 1.
Results
Pharmacological doses of GX15-070 induce cytotoxicity in CLL cells
The effect of the BH3 mimetic GX15-070 was assessed in cells from 20 patients diagnosed of CLL. The biological characteristics of these patients are summarized in Table 1 . Cells were treated with GX15-070 for 20 and 40 h, at doses ranging from 0.5 to 10 mM, and cytotoxicity was measured by Annexin V labeling. GX15-070 exerted a time-and dose-dependent cytotoxic effect in the low micromolar range. The LD 50 of GX15-070 was calculated after 20 and 40 h of incubation (Table 1) . After 20 h of treatment, the mean LD 50 was 5.95 ± 2.8 mM and decreased to 1.70 ± 0.96 mM after longer exposure (40 h ) to this inhibitor. Although CLL samples expressing high levels of ZAP-70 were sensitive to GX15-070, the LD 50 values after 40 h treatment were higher (mean LD 50 (ZAP-70 þ ) ¼ 2.11 ± 1.33 mM) than those expressing low levels of ZAP-70 (mean LD 50 (ZAP-70 À ) ¼ 1.43±0.51 mM). Noteworthy, although the small number of patients, biological response to GX15-070 appeared to be effective in the majority of CLL cases, including those bearing high-risk biological factors such as del11q and del17p.
GX15-070 activates the mitochondrial apoptotic pathway in CLL by disrupting MCL-1/BAK and BCL-2/ BIM complexes Other authors and ourselves have recently described how the BH3 mimetic GX51-070 directly activates the mitochondrial apoptotic pathway by provoking BAK release from its antiapoptotic counterpart MCL-1. 22, 26, 27 On the basis of these previous reports we performed co-immunoprecipitation experiments in order to validate the mechanism of action of GX15-070 in primary CLL cells. Cells from a representative CLL patient (patient no. 2) were treated with GX15-070 for 3 h and MCL-1 immunoprecipitation was performed in total cell extracts using NP-40 buffer. Immunodetection of BAK in the immunoprecipitated fraction (bound), using an antibody against BAK N-terminus, revealed that GX15-070 brings about BAK release from MCL-1 after short incubation times (Figure 1a) . Similar results were obtained using CHAPS buffer and BAK immunoprecipitation (data not shown). As CLL cells appeared to be especially dependent on BCL-2, 19 we also performed immunoprecipitation of BCL-2 in CHAPS extracts of cells from the same patient in an identical experimental setting. We observed that GX15-070 was also able to release the 'activator' BH3-only protein BIM from its antiapoptotic counterpart BCL-2 ( Figure 1a) . These events led to mitochondrial depolarization that was observed as early as 3 h after GX15-070 addition (DiOC 6 [3] low: control 8%; treated 19%), and culminated at 40 h with the concomitant activation of BAX and BAK proteins and PS externalization (Figure 1b) . 
levels of phosphorylated BCL-2
We have recently reported that GX15-070 is highly effective in MCL primary cells and cell lines. 22 Indeed, LD 50 at 20 h were significantly lower in MCL (2.93 ± 2.48 mM) compared to CLL (5.95±2.8 mM) primary cells (Po0.01). As we found, by a semiquantitative approach, that MCL sensitivity to GX15-070 was related to the total pool of the antiapoptotic BCL-2 family proteins, MCL-1, BCL-2 and BCL-X L protein levels were analyzed in 15 representative CLL cases, and compared to those detected in several MCL samples previously studied. 22 As shown in Figure 2a , BCL-2 protein expression was high in all CLL and MCL cells, whereas a heterogeneous expression of MCL-1 and BCL-X L proteins was observed among samples. The densitometric analysis of these proteins followed by a statistical comparative analysis, revealed no significant differences in the total antiapoptotic pool of BCL-2 proteins between the CLL and MCL groups (Figure 2b, left) . Thus, differential expression of BCL-2 antiapoptotic proteins cannot account for the lower sensitivity to GX15-070 of CLL compared to MCL cells. It has been described that BCL-2 undergoes phosphorylation in several residues, being the phosphorylation at serine 70 necessary for full antiapoptotic function and interaction with multidomain and BH3-only proapoptotic members. 12, 15 Prompted by these studies, we analyzed the expression of phosphorylated BCL-2 at serine 70 residue (pBCL-2(Ser70)), using a phospho-specific BCL-2 antibody in the same series of CLL and MCL samples (Figure 2a) . The densitometric analysis of pBCL-2(Ser70) expression followed by statistical analysis revealed that the pBCL-2/BCL-2 ratios were significantly higher in CLL cells (Po0.05) compared to those found in MCL samples (Figure 2b,  right) , possibly contributing to the lower sensitivity of CLL cells to GX15-070. As we observed lower cytotoxicity of GX15-070 in ZAP-70 þ CLL cases, we also compared pBCL-2/BCL-2 ratios in ZAP-70 þ (n ¼ 8) vs ZAP-70 À (n ¼ 12) CLL groups. The densitometric and statistical analysis showed that pBCL-2/BCL-2 ratios were significantly higher in ZAP-70 þ compared to the ZAP-70 À CLL group (Po0.05; Figure 2c ). These results suggest In all analysis, protein extract from CLL patient no. 14 was the internal control used to normalize samples analyzed in different gels.
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BCL-2 phosphorylation level modulates the sensitivity of CLL cells to GX15-070
We analyzed further the role of BCL-2 phosphorylation status at Ser70 in the sensitivity to GX15-070 using a BCL-2 phosphomimetic mutant in this residue. H2199 cells, that express very low levels of endogenous BCL-2, were transduced with BCL-2b5 or with the phosphomutant S70E-BCL-2b5. H1299 BCL-2b5 and H1299 S70E BCL-2b5 expressed comparable levels of BCL-2, although in the parental cells were under the level of detection (Figure 3a ). The analysis of the sensitivity to GX15-070, revealed that an increase in BCL-2 expression reduced the sensitivity to this drug, in accordance with previous results, 22 and more importantly, the phosphomimetic mutant S70E BCL-2b5 was more resistant to GX15-070 than BCL-2b5 expressing wt BCL-2. Moreover, immunoprecipitation of pBCL-2(ser70)-BIM complexes in CLL cells treated with GX15-070, revealed that this BH3 mimetic was not able to release BIM from pBCL-2(ser70) (data not shown). As ERK1 and ERK2 have been identified as direct kinases of BCL-2 phosphorylation, 28 we analyzed the levels of pERK in our CLL samples, observing a significant correlation (Po0.05) between the degree of ERK activation and pBCL-2/BCL-2 ratio (Figure 3b ). We next addressed whether the MEK1/ERK inhibitor PD98059 was able to inhibit BCL-2 phosphorylation, and thereby enhance the cytotoxic effect of GX15-070 in CLL cells. Treatment of CLL cells with 20 mM PD98059 for 6 h totally blocked constitutive activation of ERK1/2 and significantly reduced pBCL-2(Ser70) levels, while having no effect on BCL-2 total protein levels (Figure 3c ). The combination of PD98059 with GX15-070 was highly synergistic in cells from four representative CLL patients, reaching CIs under 0.7 in all cases (Figure 3d ). To analyze further the relevance of pBCL-2(Ser70) in the sensitivity of CLL cells to GX15-070, we explored the effect of increasing BCL-2 phosphorylation levels. As the protein phosphatase PP2A has proven to be responsible for BCL-2 dephosphorylation, 29 we tested whether its inhibition could reduce the sensitivity of CLL cells to GX15-070. Okadaic acid is the most widely used inhibitor of serine/threonine protein phosphatases and, more importantly, at the low dose used in these experiments (1 nM), okadaic acid is considered a selective inhibitor of PP2A. 30 Okadaic acid led to an accumulation of pBCL-2(Ser70) starting at 6 h, which was maintained up to 20 or 40 h (not shown) depending on individuals. Again, BCL-2 protein levels did not vary with okadaic acid treatment (Figure 3e ). Pretreatment of CLL cells with okadaic acid before GX15-070 addition significantly reduced the response of CLL cells to this BH3 mimetic (Figure 3f ). These results, taken together, further support the hypothesis that BCL-2 phosphorylation at Ser70 may well modulate sensitivity of CLL cells to GX15-070. pBCL-2(Ser70) modulates CLL sensitivity to GX150-70 P Pérez-Galán et al
Accumulation of phosphorylated BCL-2 impedes full synergistic interaction between GX15-070 and bortezomib in CLL cells
As bortezomib clinical trials in CLL have shown limited efficacy, 31 we analyzed whether CLL sensitivity to bortezomib could be enhanced by cotreatment with GX15-070, as we have previously described in MCL. 22 CLL primary cells were preincubated with several doses of GX15-070 (0.1, 0.5, 1 and 2 mM) for 20 h prior to the addition of 5 nM bortezomib for further 20 h, when cell viability was determined. The CIs were calculated for each combination and plotted against pBCL-2/ BCL-2 ratios for each patient (Figure 4a ). These CIs ranged from Figure 4 Effect of BCL-2 phosphorylation on GX15-070 plus bortezomib combination. (a) Chronic lymphocytic leukemia (CLL) cells were preincubated with GX15-070 (0.1, 0.5, 1 and 2 mM) for 20 h and then 5 nM bortezomib was added for 20 additional hours. Combination indexes (CIs) were calculated for each combination and plotted vs pBCL-2/BCL-2 ratio for each CLL sample. Linear regression and statistical significance were defined using GraphPad Prism software. (b) Cells from CLL patient no. 2 were treated with 10 nM bortezomib for the times indicated. Total protein extracts were analyzed by western blot for BCL-2, pBCL-2(Ser70) and a-tubulin expression, and pBCL-2/BCL-2 ratios were calculated. (c) Cells from CLL patient no. 3 were preincubated for 1 h with 20 mM PD98059, and then treated with 10 nM bortezomib for 5 additional hours. Total proteins extracts were analyzed for the expression of pERK, pBCL-2(Ser70), BCL-2 and a-tubulin, and pBCL-2/BCL-2 ratios calculated as above. (d) Cells from two representative CLL patients were treated with the previously indicated doses of GX15-070 alone for 40 h, together with either 5 nM bortezomib or with both 5 nM bortezomib plus 20 mM PD98059. Viability was assessed by DiOC 6 [3] labeling and fluorescence-activated cell sorting (FACS) analysis and percentage of response calculated referred to each patient control. CIs calculated as above, are indicated inside the plot for each combination.
pBCL-2(Ser70) modulates CLL sensitivity to GX150-70 P Pérez-Galán et al 0.5 (synergistic) to 1 (additive), depending on individuals, and were less than 0.4 when GX15-070 dose was increased to 2 mM. It is noteworthy that a strong correlation (Po0.01) was observed between low CI values and reduced pBCL-2/BCL-2 ratios for each GX15-050 dose analyzed. These results suggest that low levels of pBCL-2(Ser70) favor the synergistic interaction between bortezomib and GX15-070.
It has been reported that phosphorylation protects BCL-2 from ubiquitin-dependent degradation by proteasome and that proteasome inhibition leads to the accumulation of phosphorylated forms of BCL-2. 16, 17 These findings suggest that proteasome inhibition could increase pBCL-2/BCL-2 ratios, thereby limiting its synergistic interaction with GX15-070. To test this hypothesis in our model, we performed a time response analysis of pBCL-2/BCL-2 ratios in cells treated with 10 nM bortezomib. We found that pBCL-2/BCL-2 values increased gradually in the presence of this proteasome inhibitor (Figure 4b ). Considering that pharmacological inhibition of ERK1/2 inhibition reduces basal BCL-2 phosphorylation levels (Figure 3c ), we then tested whether this inhibition could also reverse bortezomib-induced BCL-2 phosphorylation. The analysis of pBCL-2 and BCL-2 protein levels in cells from a representative patient treated with 20 mM PD98059 and 10 nM bortezomib, showed that ERK1/2 reversed the accumulation of phosphorylated BCL-2 induced by bortezomib, whereas the total BCL-2 protein level remained unchanged (Figure 4c ). Following this line of evidence, we tested whether ERK1/2 inhibition by PD98059 could enhance bortezomib and GX15-070 interaction. Cells from two representative CLL patients were pretreated for 1 h with 20 mM PD98059 before the addition of GX15-070 for 20 h, and then 5 nM bortezomib for 20 additional hours. PD98059 pretreatment was shown to increase the synergistic interaction between GX15-070 and bortezomib, allowing CIs to decrease to 0.3-0.4 and ensuring higher cytotoxicities of the combination (Figure 4d ).
Discussion
Antiapoptotic BCL-2 proteins are overexpressed in most cases of CLL and have been related with the impairment of physiological apoptosis. 4 In a small percentage of CLL patients, BCL-2 protein overexpression was explained by promoter hypomethylations or translocations involving immunoglobulin genes. 32 Also, an inverse correlation between miR-15a and BCL-2 as well as between miR-16 and BCL-2 has been found. 33 However, these latter results remain controversial. 34 High levels of other antiapoptotic BCL-2 proteins such as MCL-1 and BCL-X L have been associated with survival signals coming from microenvironment. [35] [36] [37] Attempts to target BCL-2 in CLL cells using BCL-2 antisense oligonucleotides have yielded relatively low reductions in BCL-2 protein expression and modest clinical benefit. 20 Currently, a favoured strategy for BCL-2 antagonism is based on small molecules that target several antiapoptotic BCL-2 proteins by mimicking a BH3 domain. Hence, several compounds have been isolated or chemically synthesized, showing different binding specificity and affinity for these proteins and promoting apoptosis. 38 Among them, GX15-070 is a polypyrrole small-molecule pan-BCL-2 inhibitor that fits into the groove of pro-survival BCL-2 members mimicking a BH3-only protein. It has been proposed that only certain BCL-2 protein pairs involving the BH3-only proteins can associate inside cells, being BIM and PUMA able to engage all pro-survival BCL-2 proteins, whereas BAD couples preferentially BCL-2, BCL-X L and BCL-W, and NOXA binds only to MCL-1 and A1. Moreover, it is now known that proapoptotic BAK is sequestered by the antiapoptotic MCL-1 and BCL-X L , its displacement by BH3-only proteins being required for apoptosis onset.
8 GX15-070 has been found to bind to the antiapoptotic members MCL-1, BCL-2, BCL-X L and BCL-W with high affinity, and to efficiently disrupt MCL-1/BAK complexes in intact mitochondria. 21 The cytotoxic effect of GX15-070 has been described in a variety of hematologic malignancies, including MCL, 22 CLL, 23,39 multiple myeloma (MM) 27 and AML. 26 In the present work we show that, in CLL primary samples, GX15-070 induced apoptosis at low micromolar concentrations when used as a single agent. Our results demonstrate that GX15-070, due to its 'sensitizer' BH3 mimetic nature, is able to disrupt MCL-1/BAK as well as BCL-2/ BIM complexes. We assumed that the consequent release of both the 'activator' BH3-only protein BIM and the proapoptotic BAK is able to trigger the immediate collapse of mitochondrial function, as generally reported. 7 It is noteworthy that GX15-070 is also effective in CLL cells presenting alterations in P53, ATM, 13q deletions or high levels of ZAP-70 expression. However, these ZAP-70 þ cases were less sensitive than ZAP-70 À ones. Indeed, we demonstrated that ZAP-70 positivity in CLL cases was accompanied by increased amounts of phosphorylated BCL-2. Considering that BCL-2 phosphorylation at serine 70 residue is required for its antiapoptotic function, 10, 12 thus limiting its interaction with proapoptotic multidomain and BH3-only proteins, 15 it is conceivable that high levels of phosphorylated BCL-2 may directly counteract or reduce GX15-070 activity. In this regard, reduced levels of pBCL-2(Ser70) are observed in MCL cells, whereas these cells exhibit highest sensitivity to GX15-070. Both ERK1 (p44) and ERK2 (p42) kinases have been proposed to be responsible for BCL-2 phosphorylation. 28 The ERK pathway is activated in CLL cells by nurse-like cells through B-cell activating factor of the tumor necrosis factor family (BAFF) or a proliferation inducing ligand (APRIL) receptors or B-cell receptor (BCR) stimulation. 36, 37 This pathway appears to be more activated in ZAP-70 þ than in ZAP-70 -CLL cells, 40 which may account for the observed differences in levels of phosphorylated BCL-2 between these two sets of CLL patients. On the basis of these studies, we have demonstrated that the MEK1/ ERK inhibitor PD98059 is able to reduce BCL-2 phosphorylation levels and increase GX15-070 activity in CLL primary cells. As the protein phosphatase PP2A has been found to be responsible for BCL-2 dephosphorylation, 29 its inhibition by okadaic acid increases BCL-2 phosphorylation levels and reduces GX15-070 cytotoxic activity. These results, taken together, indicate that BCL-2 phosphorylation levels modulate sensitivity to GX15-070, and agree with other studies performed with the BH3 mimetic ABT-737 in AML. 41 This observation also hold true when we combined GX15-070 with the proteasome inhibitor bortezomib. Indeed, as we recently reported in MCL cells, 22 in the present work we show that this combination is also synergistic in CLL cells. However, in the CLL series the CI values calculated from bortezomib and GX15-070 combination were higher than those observed in MCL cells, indicating a lower synergistic interaction between the two compounds. In this regard, we found an inverse correlation between the CI values and the pBCL-2/BCL-2 ratios, suggesting that those low levels of phosphorylated BCL-2 also favor GX15-070 synergistic interaction with bortezomib. In addition, we found that proteasome inhibition leads to the accumulation of pBCL-2(Ser70) limiting its interaction with GX15-070. Accordingly, as ERK1/2 was responsible for BCL-2 phosphorylation at serine 70 residue, we also demonstrated that ERK1/2 inhibition by PD98059 could reverse pBCL-2(Ser70) modulates CLL sensitivity to GX150-70 P Pérez-Galán et al bortezomib-induced accumulation of phosphorylated BCL-2. Consistent with this, the addition of ERK inhibitors to CLL cultures could greatly enhance the synergistic effect of GX15-070 and bortezomib. However, in front of these observations, the mechanism underlying the synergy between bortezomib and GX15-070 necessarily overcomes the protection conferred by BCL-2 phosphorylation toward GX15-070 activity. Indeed, the combination may directly benefit from the original property of GX15-070 to induce disruption of both BAK/MCL-1 and BIM/ BCL-2 complexes, leading to the intracellular accumulation of free BIM. This process may considerably enhance the efficiency of the 'three-at-once' bortezomib-induced stabilization of the BH3-only proteins NOXA, BIK and BIM, in activating BAX/BAK complexes and inducing mitochondrial collapse. 42, 43 This hypothesis remain to be confirmed, keeping in mind that, additional factors, other than BIM, BAX and BAK proteins, may account for GX15-070 to allow cell sensitization to bortezomib, such as the activation of the G 2 cell-cycle checkpoint by both agents. 26, 44 In conclusion, the present study demonstrates that GX15-070 efficiently kills CLL cells and that high levels of BCL-2 phosphorylation at Ser70, due to MEK1/ERK pathway activation of CLL cells, reduce its activity and synergism with the proteasome inhibitor bortezomib. These results support the role of BCL-2 phosphorylation as a mechanism of resistance to BH3 mimetic compounds and suggest that combination approaches including ERK inhibitors, could enhance BH3 mimetic activity, both alone and in combination with proteasome inhibitors.
